Amylin Pharmaceuticals, Inc., Eli Lilly and company receive EU OK for new Byetta use (BioSpace, 23 March 2012)
The European Commission has accepted an extension to the marketing authorisation for type 2 diabetes treatment exenatide (Byetta) as an adjunctive therapy to basal insulin, with or without metformin and/or pioglitazone (Actos).
Full article